MedTrace Logo

An Expanded Access Program for SYN023 in Rabies Treatment

NCT07706907 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2026-07-17

No results posted yet for this study

Summary

This sponsor-initiated Expanded Access Program provides compassionate-use SYN023, a dual monoclonal antibody cocktail (zamerovimab + mazorelvimab) targeting rabies virus glycoprotein, for US patients with confirmed or suspected life-threatening rabies lacking adequate alternative therapies.

Conditions

  • Rabies

Interventions

DRUG

Zamerovimab and Mazorelvimab Injection

SYN023 may be administered with rabies treatments according to the local standard of care; local standard of care may include the Milwaukee Protocol if the treating clinician and patient so choose.

Sponsors & Collaborators

  • Synermore Biologics (Suzhou) Co., Ltd.

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07706907 on ClinicalTrials.gov